Flavone acetic acid (FAA) with recombinant interleukin-2 (rIL-2) in advanced malignant melanoma. III: Cytokine studies. by Haworth, C, O'Reilly, S, Chu, E, Rustin, G, Feldmann, M

Robotic assistance during cochlear implantation: the rationale for consistent, controlled speed of electrode array insertion by Rustin G. Kashani, Allan Henslee, Rick F. Nelson, Marlan R. Hansen

Get full text

Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. by Maxwell, R, Wilson, J, Prise, V, Vojnovic, B, Rustin, G, Lodge, M, Tozer, G

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. by Rustin, G, Galbraith, S, Anderson, H, Stratford, M, Folkes, L, Sena, L, Gumbrell, L, Price, P

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial by Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial. by Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, MR, Ward, T, Dive, C

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors by Nathan, P, Judson, I, Padhani, A, Harris, A, Carden, C, Smythe, J, Collins, D, Leach, M, Walicke, P, Rustin, G

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results by Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Shreeves, G, Poupard, L, Walicke, P, Balkissoon, J, Chaplin, D, Rustin, G

Shortwave infrared otoscopy for diagnosis of middle ear effusions: a machine-learning-based approach by Rustin G. Kashani, Marcel C. Młyńczak, David Zarabanda, Paola Solis-Pazmino, David M. Huland, Iram N. Ahmad, Surya P. Singh, Tulio A. Valdez

Get full text

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. by Zweifel, M, Jayson, G, Reed, N, Osborne, R, Hassan, B, Ledermann, J, Shreeves, G, Poupard, L, Lu, S, Balkissoon, J, Chaplin, D, Rustin, G

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. by Rustin, G, Shreeves, G, Nathan, P, Gaya, A, Ganesan, T, Wang, D, Boxall, J, Poupard, L, Chaplin, D, Stratford, MR, Balkissoon, J, Zweifel, M

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors. by Patterson, D, Zweifel, M, Middleton, MR, Price, P, Folkes, L, Stratford, MR, Ross, P, Halford, S, Peters, J, Balkissoon, J, Chaplin, D, Padhani, A, Rustin, G

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. by Nathan, P, Zweifel, M, Padhani, A, Koh, D, Ng, M, Collins, D, Harris, A, Carden, C, Smythe, J, Fisher, N, Taylor, N, Stirling, J, Lu, S, Leach, M, Rustin, G, Judson, I

An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib by Mateo, J, Moreno, V, Gupta, A, Kaye, S, Dean, E, Middleton, M, Friedlander, M, Gourley, C, Plummer, R, Rustin, G, Sessa, C, Leunen, K, Ledermann, J, Swaisland, H, Fielding, A, Bannister, W, Nicum, S, Molife, L

Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. by Shaked, Y, Tang, T, Woloszynek, J, Daenen, L, Man, S, Xu, P, Cai, SR, Arbeit, J, Voest, E, Chaplin, D, Smythe, J, Harris, A, Nathan, P, Judson, I, Rustin, G, Bertolini, F, Link, D, Kerbel, R

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas. by Meyer, T, Gaya, A, Dancey, G, Stratford, MR, Othman, S, Sharma, S, Wellsted, D, Taylor, N, Stirling, J, Poupard, L, Folkes, L, Chan, P, Pedley, R, Chester, K, Owen, K, Violet, J, Malaroda, A, Green, A, Buscombe, J, Padhani, A, Rustin, G, Begent, R

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial by Oza, A, Cook, A, Pfisterer, J, Embleton, A, Ledermann, J, Pujade-Lauraine, E, Kristensen, G, Carey, M, Beale, P, Cervantes, A, Park-Simon, T, Rustin, G, Joly, F, Mirza, M, Plante, M, Quinn, M, Poveda, A, Jayson, G, Stark, D, Swart, A, Farrelly, L, Kaplan, R, Parmar, M, Perren, T